Apple

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Apple sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 2 currently recruiting 7 completed top decile by trial count

Apple: 12 sponsored US clinical trials, 2 recruiting.

Apple sponsors 12 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. The most-studied condition in this pipeline is Atrial Fibrillation, with 2 trials.

Top-decile sponsor footprint

Apple ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

What is open in the Apple pipeline

2 recruiting of 12 indexed (17% open); 7 completed (58%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Atrial Fibrillation (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Apple: open-pipeline peers nationwide

Peers matched on 12 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Apple sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 468101214 0%5%10%15%20% Total trials Recruiting share AppleAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAdageneAgendiaAkamis BioAnthos Therapeutics
Apple sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Apple sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Apple page

12 registered trials is a research-attention snapshot, not an endorsement of Apple or any single study.

  • 2 of Apple's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Atrial Fibrillation is the condition Apple studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atrial Fibrillation trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Apple pipeline card: 12 registered trials from official public datasets.Report a data error.